Abstract:(1) Background: Recently, sodium–glucose cotransporter-2 inhibitors (SGLT2Is) have been reported to significantly reduce renal cell carcinoma (RCC) risk. However, the effect between individual SGLT2Is on RCC incidence in patients with type 2 diabetes (T2D) or heart failure is unclear. We conducted an observational analysis to explore type disparity in the prescription of SGLT2Is on RCC risk. (2) Methods: A nationwide retrospective cohort study using the Health and Welfare Data Science Center database (2016–2021) was conducted. Patients aged ≥40 years who took SGLT2Is were designated as the SGLT2I group, whereas propensity score 1:1-matched randomly selected patients without SGLT2Is were assigned to the non-SGLT2I group. The primary outcome was the risk of incident RCC between individual SGLT2Is. Multiple Cox regression modeling was conducted to analyze the association between individual SGLT2I use and RCC risk. (3) Results: After a 5.5-year follow-up, SGLT2I use was associated with a significantly lower risk of incident RCC (hazard: 0.62; 95% confidence interval [CI]: 0.44–0.89). Compared with non-users and after adjusting for the index year, sex, age, comorbidities, concurrent medication, and the risk of developing RCC, the hazard ratios of dapagliflozin, canagliflozin, and empagliflozin were 0.66 (95% CI: 0.53–0.83), 0.84 (95% CI: 0.46–1.30), and 0.71 (95% CI: 0.56–0.90), respectively. (4) Conclusions: Our data show a type-based effect of SGLT2Is on RCC risk. The type-based effect of SGLT2Is should be further studied for better clinical management information and for reducing RCC incidence in patients with T2D.

What problem does this paper attempt to address?

This paper aims to explore whether there are differences in the effects of different types of sodium - glucose cotransporter 2 inhibitors (SGLT2Is) on the incidence of renal cell carcinoma (RCC) in patients with type 2 diabetes. Specifically, researchers hope to evaluate whether these drugs can reduce the risk of RCC and whether there are significant differences among different types of SGLT2Is by analyzing the usage of different SGLT2Is. ### Research Background - **Type 2 Diabetes (T2D) and Renal Cell Carcinoma (RCC)**: In recent years, the incidences of type 2 diabetes and renal cell carcinoma have increased globally, especially in developing countries. Diabetes is considered a risk factor for renal cell carcinoma, and patients with type 2 diabetes who also have renal cell carcinoma usually have a poor prognosis. - **The Role of SGLT2Is**: SGLT2Is are a class of drugs used to treat type 2 diabetes and heart failure. They reduce blood - glucose reabsorption by inhibiting the SGLT2 protein in the kidneys. Recent studies have shown that SGLT2Is may have anti - tumor effects and can reduce the risk of cancer. ### Research Objectives - **Primary Objective**: To explore whether there are differences in the effects of different types of SGLT2Is on the incidence of renal cell carcinoma in patients with type 2 diabetes. - **Specific Questions**: - Can different types of SGLT2Is (such as dapagliflozin, canagliflozin, and empagliflozin) all reduce the risk of RCC? - Are there significant differences among these drugs? ### Research Methods - **Research Design**: A retrospective cohort study using data from the Taiwan National Health Insurance Research Database (NHIRD). - **Study Population**: Patients with type 2 diabetes aged ≥40 years, divided into SGLT2I user group and non - user group, and the two groups were matched by propensity score (1:1). - **Primary Outcome**: The incidence of RCC, defined by ICD - 10 - CM code C64. - **Statistical Analysis**: A time - dependent Cox proportional - hazards regression model was used to analyze the association between SGLT2I use and RCC risk. ### Main Findings - **Overall Results**: The use of SGLT2I was associated with a significant reduction in RCC risk (hazard ratio: 0.62; 95% confidence interval: 0.44–0.89). - **Results for Different Types of SGLT2Is**: - Dapagliflozin: Hazard ratio 0.66 (95% confidence interval: 0.53–0.83) - Canagliflozin: Hazard ratio 0.84 (95% confidence interval: 0.46–1.30) - Empagliflozin: Hazard ratio 0.71 (95% confidence interval: 0.56–0.90) ### Conclusions - **Main Conclusions**: There are differences among different types of SGLT2Is in reducing the RCC risk in patients with type 2 diabetes. Dapagliflozin and empagliflozin show significant protective effects, while the effect of canagliflozin is not significant. - **Clinical Significance**: These findings provide important information for clinicians and are helpful for better managing the RCC risk in patients with type 2 diabetes. ### Future Research Directions - **Further Research**: More prospective studies are needed to verify these findings and explore the specific mechanisms of different types of SGLT2Is in terms of RCC risk.

Type Disparity in Sodium–Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study

Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention: A Propensity-Matched Analysis

Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter‐2 inhibitors

Lower Risks of Incident Colorectal Cancer in SGLT2i Users Compared to DPP4i Users: A Propensity Score-matched Study with Competing Risk Analysis

Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching National Cohort Study

Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: a propensity score-matched study with competing risk analysis

Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis

Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study

931-P: Real-World Study on the Effect of SGLT2 Inhibitors in Patients with Type 2 Diabetes in China

880-P: Effects of Sodium–Glucose Cotransporter-2 Inhibitors on the Risk of Atrial Fibrillation in Older Adults with Type 2 Diabetes

Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.

Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study

Impact of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in patients with chronic kidney disease: propensity score matched analysis

Renal outcomes of combination therapy with sodium-glucose cotransporter 2 inhibitors plus renin-angiotensin system blockers in patients with type 2 diabetes mellitus: A population-based cohort study

Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

SGLT ‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors

Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?

Association of sodium–glucose cotransporter‐2 inhibitors and the risk of retinal vascular occlusion: A real‐world retrospective cohort study in Taiwan

Disparities in Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor among Patients with Different Extents of Renal Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: A mendelian randomization and population-based cohort study